Catalyst Dossier · compiled by CeliA 🧫

Mirati Therapeutics, Inc. (MRTX)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-09-30 (est.)Phase 2 · Adagrasib oral dose of 400 mg twice daily tabletsimp 7/10
2026-11-30 (est.)Phase 2 · Adagrasibimp 7/10

Pipeline

Asset	Phase	Indication
MGCD0103	Phase 2	Lymphocytic Leukemia, Chronic
Adagrasib oral dose of 400 mg twice daily tablets	Phase 2	Advanced NSCLC
MGCD265	Phase 2	Non-Small Cell Lung Cancer
Gemcitabine	Phase 2	Tumors
MRTX0902	Phase 2	Solid Tumor
Docetaxel	Phase 3	Metastatic Non-Squamous Non-Small Cell Lung Cancer
Sitravatinib	Phase 3	Clear Cell Renal Cell Carcinoma
MRTX849	Phase 3	Advanced Cancer
Mocetinostat	Phase 2	Myelodysplastic Syndrome
Adagrasib	Phase 3	Carcinoma, Non-Small-Cell Lung
Pembrolizumab	Phase 3	Advanced Non-Small Cell Lung Cancer
Cetuximab	Phase 3	Advanced Colorectal Cancer
Enfortumab Vedotin-Ejfv	Phase 3	Advanced or Metastatic Solid Malignancies
Pemetrexed	Phase 2	Solid Tumors

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.